Introduction
============

A significant proportion of deaths in South Korea can be attributed to cancer, with cancer mortality rates being reported as 150.9 per 100,000 individuals in 2014 \[[@b1-crt-2016-525]\]. Cancer is known to impose large socioeconomic burdens on society because it incurs substantial direct healthcare costs, as well as indirect costs such as those associated with caregiving and lost productivity \[[@b2-crt-2016-525]\]. To address the burden of cancer, the South Korean government implemented the National Cancer Screening Program in 1999 to provide screening for the five most common sites of cancer; namely, stomach, liver, colorectal, breast, and the cervix uteri.

The World Health Organization reported that a 93% reduction in the incidence of cervical cancer can be expected in response to introduction of screening programs \[[@b3-crt-2016-525]\]. Moreover, previous studies have shown that national cervical cancer screening is cost effective at reducing cervical cancer incidence and mortality in South Korea \[[@b4-crt-2016-525],[@b5-crt-2016-525]\]. Cho et al. \[[@b6-crt-2016-525]\] demonstrated that the national cervical cancer screening program was effective in terms of life years saved (LYS), with a threshold of \$32,272 (\$1=1,100 Korean won \[KRW\]) per person, which was the gross domestic product (GDP) of South Korea in 2012 (incremental cost effectiveness ratio \[ICER\], 7,581,679 KRW/LYS). Similarly, another study cited the annual conduction of Papanicolaou smear cytology (Pap) to females aged 30 or above as the most cost effective strategy in quality adjusted life years (QALY) \[[@b7-crt-2016-525]\].

Despite the potential benefits of national cervical cancer screening uptake, examination rates are reportedly lower in South Korea (approximately 66%) than in other countries including the United States (74%) and the United Kingdom (78%) \[[@b8-crt-2016-525]\]. Disparities were also found among individuals of various socioeconomic status, and particularly among those of different regional status \[[@b8-crt-2016-525]\]. Hence, such tendencies require the need for a cost effectiveness analysis that takes into account regional inequality and distribution of health effects, in addition to previous research that has aimed to maximize population health using restricted resources \[[@b9-crt-2016-525]\].

Despite such importance, few South Korean studies have included cost effectiveness analysis of cervical cancer based on regional disparities in cancer screening. A previous study targeting Taiwanese participants concluded that individuals who received group education programs had higher screening rates than those who received introduction pamphlets through the mail \[[@b10-crt-2016-525]\]. Another study in the United States demonstrated that sending introduction pamphlets by mail can increase cervical cancer screening rates by about 12% \[[@b11-crt-2016-525]\]. Therefore, this study was conducted to evaluate cost effectiveness of methods with the aim of identifying strategies that can improve the South Korean national cervical cancer screening uptake rate. Further analysis was also performed considering regional disparities in screening rates using the distributional cost effectiveness analysis method, which specifically considers health inequalities under the cost effectiveness framework \[[@b12-crt-2016-525]\].

Materials and Methods
=====================

1\. Model structure: cost-effectiveness analysis

A Markov simulation model was developed using TreeAge Pro (TreeAge Software, Williamstown, MA). The model structure is illustrated in [Fig. 1](#f1-crt-2016-525){ref-type="fig"}. Individuals enter the model in a healthy, well state. With time, a proportion of the individuals are found to be susceptible to human papillomavirus (HPV) infection, which can progress to cervical intraepithelial neoplasia (CIN) and cancer.

The model incorporates disease regression, and individuals immediately diagnosed with CIN move to the well history state after treatment. The well history state can lead to an increase in screening rates as individuals diagnosed with CIN are likely to become cautious about CIN and cancer. If cancer progresses, individuals can only move to the cancer cured state if they receive treatment and survive for 5 years. These individuals are assumed to be cancer free and considered to not receive further screening. A death state is present in each status, and all individuals are transferred to the death state 100 years after the start of the cohort.

Because this study aimed to identify strategies that can improve screening uptake, four screening strategies were evaluated: (1) the current strategy, which is the presently followed national cancer screening program in South Korea. In this strategy, all females aged 20 or above receive the Pap smear test biennially, and individuals screened positive obtain further secondary examinations. (2) The strong screening recommendation to target regions strategy, which, in addition to the current strategy, sends strong screening recommendation posts to target populations residing in areas with higher than average mean mortality rates. (3) The regular universal screening recommendation strategy, which dispatches regular screening recommendation posts to all target populations. (4) The strong universal screening recommendation strategy, which mails strong screening recommendations to all target populations. The four strategies are presumed to result in a difference of screening uptake rates: (1) current: biennial Pap to females aged 20 or above (reference), (2) strong screening recommendation by mail to target regions, (effect, 12% increase in screening uptake; cost, 1,000 KRW per person), (3) regular universal screening recommendation by mail, (effect, 6% increase in screening uptake; cost, 500 KRW per person), and (4) strong universal screening recommendation by mail (effect, 12% increase in screening uptake; cost, 1,000 KRW per person).

A cohort of 1,000,000 women aged 20 or above without a history of cervical cancer was included in the simulation model because the national cervical cancer screening program in South Korea targets this group \[[@b13-crt-2016-525]\]. The model simulated each cohort member based on age-specific cervical cancer incidence and mortality rates. Analysis was conducted using the restricted societal perspective, which accounted for direct medical costs, indirect costs, and caregiving costs, but excluded human productivity costs.

2. Model parameters
-------------------

Age- and region-specific screening uptake rates were obtained from the 2012 Korean Community Health Survey (KCHS) ([Table 1](#t1-crt-2016-525){ref-type="table"}). The KCHS is a nationally representative survey conducted in 253 local districts of South Korea by the Korean Centers for Disease Control and Prevention with the goal of understanding disease prevalence and morbidity patterns. Age- and region-specific mortality rates were calculated by eliminating cancer mortality rates from the general mortality rate reported by Statistics Korea in 2012 ([Table 1](#t1-crt-2016-525){ref-type="table"}).

Cervical cancer stages were based on the Surveillance, Epidemiology, and End Results (SEER). As SEER statistics on cervical cancer transition probabilities were unavailable, International Federation of Gynecology and Obstetrics (FIGO) stages were converted to SEER stages using statistics reported in the FIGO annual report \[[@b14-crt-2016-525],[@b15-crt-2016-525]\]. [Table 2](#t2-crt-2016-525){ref-type="table"} presents the age- and stage-specific 5-year mortality rates of cervical cancer in South Korea. As SEER cancer stage based transition probabilities were not available in South Korea, this information was obtained by converting FIGO cancer stage based transition probabilities \[[@b15-crt-2016-525]\].

HPV infection rates were attained using simulation results reported by Ko et al. \[[@b7-crt-2016-525]\], who took into consideration rate of HPV infection and sexual experience ([Table 3](#t3-crt-2016-525){ref-type="table"}). The CIN transition probabilities were obtained from the National Health Insurance data ([Table 3](#t3-crt-2016-525){ref-type="table"}) \[[@b16-crt-2016-525]\]. Parameters pertaining to the regression probabilities in the precancerous stages were obtained from previous cost effectiveness analysis of cervical cancer in Thailand as no local information was available for Korea ([Table 3](#t3-crt-2016-525){ref-type="table"}) \[[@b17-crt-2016-525],[@b18-crt-2016-525]\]. Cervical cancer transition probabilities were calculated by transforming FIGO stages to SEER stages, as described above ([Table 3](#t3-crt-2016-525){ref-type="table"}) \[[@b14-crt-2016-525]\].

3. Costs
--------

Direct and indirect costs were included in this study, as shown in [Table 4](#t4-crt-2016-525){ref-type="table"} \[[@b19-crt-2016-525],[@b20-crt-2016-525]\]. Direct medical costs included those incurred from the Pap smear test and, with regard to individuals who screened positive, those associated with colposcopy, biopsy, and HPV DNA tests. The average usage rates of the three examinations were used because information regarding the rate of each examination was not available. Direct tests also included consultation costs and treatment costs for individuals diagnosed with precancerous states or cancer. Treatment costs were calculated based on a previous study conducted by Goldhaber-Fiebert because studies conducted in South Korea did not measure costs by disease stage \[[@b21-crt-2016-525]\]. Indirect costs included time, transportation, and caregiving costs. Discount rates were assumed to be 1%.

4. Utilities and screening effects
----------------------------------

Age-specific health state utilities were attained using the EuroQol-5D results of the KCHS. Precancerous state patient utilities were adjusted using outcomes from patient surveys \[[@b16-crt-2016-525]\] and cancer state utilities were calculated based on previous studies \[[@b22-crt-2016-525],[@b23-crt-2016-525]\]. Sensitivity and specificity of the Pap smear test were determined from a meta-analysis of experimental studies in South Korea \[[@b7-crt-2016-525]\]. Individuals tested positive on the Pap smear test were assumed to fully participate in secondary tests and the sensitivity of secondary tests were set at 100%.

5\. Distributional cost effectiveness analysis

Distributional cost effectiveness analysis aims to adjust the total effectiveness outcome with an inequality index so that strategies with larger health disparity result in lower total effectiveness \[[@b24-crt-2016-525]\]. A method for distributional cost effectiveness has been introduced by the Centre for Health Economics in 2014, which can be expressed using the Atkinson Inequality Index in Eq. ([1](#DF1){ref-type="disp-formula"}) \[[@b12-crt-2016-525]\]. The Atkinson Inequality Index is a function of inequality aversion, namely public aversion to health disparity, that is measured using public opinion regarding the ideal rate of exchange between the health of individuals with the best and worst health \[[@b24-crt-2016-525]\]. After calculating the Atkinson Inequality Index for every intervention deliberated in this study, the Atkinson ICER can be measured using Eq. ([2](#DF2){ref-type="disp-formula"}), which adjusts the obtained ICER by the Atkinson Inequality Index \[[@b24-crt-2016-525]\]. The Atkinson ICER can assess which strategy considered in an analysis is the most cost-effective when inequality aversion increases in a society \[[@b24-crt-2016-525]\]. In this study, the Atkinson ICER was used to account for regional disparities in screening rates and to investigate health inequalities under the cost effectiveness framework.
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Results
=======

The results of the cost effectiveness analysis of the four compared strategies are presented in [Table 5](#t5-crt-2016-525){ref-type="table"}. The strong universal screening recommendation strategy had the highest QALY effectiveness per person, whereas the current strategy incurred the lowest amount of cost. With the threshold set at \$25,990 (KRW 29,901,550), the 2016 GDP of South Korea, the strong universal screening recommendation strategy was the most effective strategy, with an effectiveness of 44.6734 QALY and an ICER value of KRW 11,506,849. In terms of efficiency, the strong screening recommendation to target regions was the most efficient, with an ICER value of KRW 7,361,145.

[Table 6](#t6-crt-2016-525){ref-type="table"} presents the cost effectiveness analysis results of the four strategies by the 16 provincial regions of South Korea. Under the "current" strategy, Seoul had the highest QALYs per capita, whereas Ulsan showed the lowest QALYs per capita. Similar tendencies were found under the strong universal screening recommendation strategy. In the strong screening recommendation to target regions strategy, Busan had the highest QALYs per capita and Ulsan the lowest QALYs per capita.

[Fig. 2](#f2-crt-2016-525){ref-type="fig"} presents the results of the distributional cost effectiveness analysis, showing the Atkinson ICER of the four strategies examined. When an identical threshold was utilized, the Atkinson ICER of all four strategies remained under the threshold value as inequality aversion increased. The cost effectiveness of the four strategies also increased as inequality aversion increased, in particular that of the strong screening recommendation to target regions strategy.

Discussion
==========

Studies have demonstrated that the national cervical cancer screening program in South Korea is cost effective \[[@b4-crt-2016-525]-[@b7-crt-2016-525]\]. However, screening uptake rates remain low compared to other more economically developed countries and show regional disparities, requiring implementation of effective strategies for improvement. To the best of our knowledge, this is the first study to investigate the required strategies through a cost effectiveness analysis in South Korea. Previous studies have examined investments in educational professionals, local community group education, mailing of pamphlets, and consultation volunteers as approaches to enhance screening rates and found mailings of pamphlets and consultation volunteers to be effective \[[@b10-crt-2016-525],[@b11-crt-2016-525],[@b25-crt-2016-525]\]. Considering the requisite resources of the four approaches investigated, mailing of pamphlets was selected as a realistic and applicable scheme. Hence, this study investigated the cost effectiveness of four strategies, current, strong screening recommendation to target regions, regular universal screening recommendation, and strong universal screening recommendation. The results indicated that the ICER values of all four strategies were under the threshold value of \$25,990 (KRW 29,901,550), and that the strong screening recommendation to target regions had the highest efficiency, whereas the strong universal screening recommendation had the highest effectiveness. Therefore, all four strategies investigated rated within the ICER threshold value and may be utilized by policy makers focusing on effectiveness or efficiency.

Another aspect to contemplate by policy makers is the conceivable effect of each strategy on regional disparity because South Korea shows discrepancies between regions in national cervical cancer screening rates. This was reflected using the Atkinson ICER, which indicated the strong screening recommendation to target regions strategy was the most efficient. The ICER value of this strategy decreased the most; thus, its cost effectiveness can be seen to have improved compared to other strategies. This results as the change in the denominator of the Atkinson ICER (ΔE) decreases for strategies more unequal to the 'current' strategy and increases for strategies less unequal to the "current" strategy. The tendencies presented in the study findings are similar to those of a previous study that investigated the distributional cost effectiveness of the national colorectal cancer screening program \[[@b24-crt-2016-525]\]. This study also found the strong screening recommendation to target regions strategy to be most efficient \[[@b24-crt-2016-525]\]. However, the ICER value decreased in a comparatively steep manner as inequality aversion increased, revealing that health disparities are likely to decline in a comparatively larger amount if the strong screening recommendation to target regions strategy is implemented.

The findings of this study revealed that addressing health inequality aversion can be important in the process of framing health policies. This study offers new insights by investigating the distributional cost effectiveness of the national cervical cancer screening program in South Korea. It is also unique in that it examined different strategies applicable with the goal of improving national cervical cancer screening rates because screening rates in South Korea have been reported to be relatively low, despite its proven cost effectiveness. However, this study also had its limitations. Specifically, age- and region-specific national cervical cancer screening rates were obtained from the KCHS because no other data were available. The KCHS does not distinguish between public and private cervical cancer screening, and screening rates may have been overestimated, which also infers a possible overestimation of the cost measures used in this study. Second, HPV infection, precancerous, and cancer transition probabilities data were not based on South Korean data because they were unavailable. Hence, cost and effectiveness may have again been overestimated as sexual lifestyles tend to be more conservative in South Korea than in other Western countries \[[@b16-crt-2016-525]\]. Third, although it can be assumed that disease transition probabilities will differ between regions, our study was unable to account for such characteristics because of a lack of data. These assumptions may have led to underestimation of the inequality measured. This limitation has also been mentioned in previous studies and necessitates the measurement of inequality variables. Finally, because this study is the first distributional cost effectiveness study of the national cervical cancer screening program in South Korea, no other results were available to compare with the findings presented.

In conclusion, analysis of the cost effectiveness of the national cervical cancer screening program in South Korea revealed the strong screening recommendation to target regions strategy to be the most cost effective approach. Similar tendencies were found when societal inequality aversion increased under the distributional cost effectiveness analysis, which accounted for regional disparities in screening uptake rates. As efficiency and equity are the two main objectives concurrently sought in healthcare, the findings of this study imply the need to develop appropriate economic evaluation methodologies to assess healthcare policies.
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###### 

2012 specific cervical cancer screening and mortality rates according to region and age

  Age (yr)        Seoul           Daegu           Daejun          Incheon         Gwangju         Ulsan           Gyeonggi        Busan                                                                                                                           
  --------------- --------------- --------------- --------------- --------------- --------------- --------------- --------------- --------------- --------------- --------------- --------------- --------------- --------------- --------------- --------------- --------
  20-24           0.0411          0.0002          0.0405          0.0002          0.02            0.0002          0.0417          0.0003          0.01            0.0003          0.0598          0.0005          0.0430          0.0002          0.0312          0.0003
  25-29           0.1814          0.0003          0.1538          0.0005          0.2215          0.0004          0.202           0.0004          0.1445          0.0004          0.1986          0.0003          0.2201          0.0003          0.1347          0.0005
  30-34           0.4076          0.0005          0.3503          0.0005          0.4534          0.0003          0.4314          0.0005          0.3434          0.0005          0.4128          0.0005          0.4591          0.0004          0.4019          0.0006
  35-39           0.5172          0.0005          0.4972          0.0006          0.4821          0.0005          0.5117          0.0005          0.5174          0.0007          0.4765          0.0005          0.5542          0.0005          0.4427          0.0006
  40-44           0.6364          0.0007          0.5444          0.0008          0.6361          0.0009          0.6131          0.0009          0.6277          0.0008          0.6606          0.0009          0.6590          0.0008          0.6024          0.0009
  45-49           0.6557          0.0011          0.6069          0.0011          0.6997          0.0013          0.6232          0.0012          0.6985          0.0011          0.6575          0.0010          0.6705          0.0012          0.6336          0.0013
  50-54           0.6918          0.0014          0.6545          0.0018          0.7912          0.0013          0.6117          0.0016          0.6912          0.0017          0.6426          0.0017          0.686           0.0016          0.6472          0.0017
  55-59           0.7126          0.0019          0.6391          0.0020          0.7406          0.0024          0.6227          0.0023          0.6794          0.0023          0.6207          0.0022          0.694           0.0023          0.6596          0.0024
  60-64           0.6837          0.0029          0.5527          0.0034          0.6667          0.0036          0.6176          0.0040          0.7135          0.0035          0.6194          0.0025          0.6414          0.0035          0.6223          0.0038
  65-69           0.5854          0.0052          0.4957          0.0065          0.6393          0.0070          0.5186          0.0067          0.5938          0.0059          0.4356          0.0071          0.5811          0.0062          0.6098          0.0066
  70-74           0.5498          0.0105          0.3798          0.0128          0.4956          0.0126          0.4113          0.0133          0.5504          0.0135          0.3556          0.016           0.4839          0.0125          0.4736          0.014
  75-79           0.3801          0.0225          0.2470          0.0246          0.3882          0.0261          0.3363          0.0259          0.4433          0.0276          0.3429          0.0302          0.3668          0.0250          0.3503          0.0301
  80-84           0.197           0.0802          0.1765          0.0936          0.2979          0.0868          0.1818          0.0859          0.1892          0.0951          0.0606          0.1014          0.2284          0.0837          0.1741          0.0940
  ≥ 85            0.1111                          0.037                           0.2188                          0.0723                          0.3913                          0.0952                          0.113                           0.1333          
                                                                                                                                                                                                                                                                  
                  **Gangwon**     **Chungbuk**    **Chungnam**    **Jeonbuk**     **Jeonnam**     **Gyeongbuk**   **Gyeongnam**   **Jeju**                                                                                                                        
  **Screening**   **Mortality**   **Screening**   **Mortality**   **Screening**   **Mortality**   **Screening**   **Mortality**   **Screening**   **Mortality**   **Screening**   **Mortality**   **Screening**   **Mortality**   **Screening**   **Mortality**   
                                                                                                                                                                                                                                                                  
  20-24           0.0639          0.0003          0.0519          0.0002          0.0641          0.0004          0.0145          0.0004          0.0558          0.0003          0.0215          0.0003          0.0265          0.0002          0.0196          0.0004
  25-29           0.2129          0.0003          0.2374          0.0005          0.2169          0.0004          0.1991          0.0004          0.1528          0.0004          0.1689          0.0004          0.1838          0.0005          0.1553          0.0008
  30-34           0.4269          0.0006          0.4092          0.0006          0.3824          0.0006          0.3684          0.0005          0.3217          0.0006          0.4048          0.0007          0.4007          0.0007          0.3459          0.0005
  35-39           0.4919          0.0008          0.5047          0.0007          0.4991          0.0006          0.5090          0.0008          0.4803          0.0009          0.4393          0.0007          0.5091          0.0006          0.5126          0.0007
  40-44           0.5819          0.0010          0.6117          0.0011          0.6124          0.0012          0.5919          0.0010          0.6163          0.0009          0.563           0.001           0.6304          0.0009          0.5506          0.0012
  45-49           0.6185          0.0014          0.6399          0.0013          0.6549          0.0011          0.6596          0.0014          0.6064          0.0013          0.5707          0.0015          0.6501          0.0012          0.6100          0.0016
  50-54           0.6723          0.0021          0.6766          0.0023          0.6491          0.0018          0.6960          0.0021          0.6347          0.0020          0.5843          0.0016          0.652           0.0018          0.6809          0.0016
  55-59           0.669           0.0026          0.6875          0.0022          0.6404          0.0029          0.6650          0.0028          0.6579          0.0022          0.5921          0.0025          0.6372          0.0024          0.6335          0.0018
  60-64           0.6237          0.0041          0.6089          0.0040          0.6022          0.0043          0.6848          0.0045          0.6310          0.0032          0.5611          0.0035          0.5894          0.0038          0.6293          0.0039
  65-69           0.5851          0.0069          0.5725          0.0067          0.5415          0.0072          0.5592          0.0064          0.6111          0.0068          0.5026          0.006           0.4882          0.0066          0.5000          0.0047
  70-74           0.4893          0.0125          0.4814          0.0125          0.4762          0.0147          0.5455          0.0127          0.5115          0.0120          0.4059          0.013           0.4107          0.0125          0.3772          0.0087
  75-79           0.3925          0.0239          0.3582          0.0245          0.3579          0.0264          0.4347          0.0240          0.4812          0.0246          0.3063          0.0254          0.2894          0.0283          0.3009          0.0208
  80-84           0.2351          0.0844          0.2402          0.0799          0.1889          0.0888          0.3000          0.0823          0.3122          0.0838          0.1943          0.0849          0.1761          0.0871          0.1909          0.0735
  ≥ 85            0.1321                          0.1917                          0.0989                          0.1714                          0.1895                          0.0767                          0.0417                          0.1014          

###### 

Age- and site-specific cervical cancer mortality rates

  Age (yr)       Mortality rate                           
  -------------- ---------------- ------- ------- ------- -------
  **Local**                                               
   20-29         0.039            0.093   0.127   0.147   0.167
   30-39         0.017            0.057   0.089   0.105   0.117
   40-49         0.013            0.038   0.062   0.073   0.091
   50-59         0.015            0.054   0.089   0.118   0.140
   60-69         0.027            0.067   0.114   0.143   0.157
   70-79         0.048            0.115   0.146   0.191   0.214
   ≥ 80          0.113            0.223   0.357   0.392   0.567
  **Regional**                                            
   20-29         0.177            0.155   0.057   0.000   0.035
   30-39         0.100            0.131   0.055   0.043   0.026
   40-49         0.087            0.133   0.072   0.035   0.024
   50-59         0.090            0.103   0.073   0.034   0.033
   60-69         0.082            0.097   0.073   0.042   0.049
   70-79         0.107            0.126   0.058   0.069   0.054
   ≥ 80          0.206            0.191   0.124   0.079   0.068
  **Distant**                                             
   20-29         0.737            0.058   0.026   0.000   0.040
   30-39         0.589            0.206   0.058   0.025   0.070
   40-49         0.491            0.190   0.081   0.052   0.026
   50-59         0.505            0.195   0.075   0.054   0.011
   60-69         0.508            0.195   0.073   0.05    0.000
   70-79         0.533            0.153   0.035   0.028   0.022
   ≥ 80          0.674            0.089   0.068   0.096   0.002

###### 

Cervical cancer screening program model parameters

  Parameter                                       Value
  ----------------------------------------------- --------
  **HPV infection rate**                          
   Age (yr)                                       
    20-29                                         0.24
    30-39                                         0.14
    40-49                                         0.13
    50-59                                         0.09
    60-69                                         0.03
    ≥ 70                                          0.01
  **Precancerous state transition probability**   
   State                                          
    CIN1 known → CIN2/3 known                     8.31
    CIN1 unknown → CIN2/3 unknown                 13.00
    CIN2/3 known → Local known                    2.14
    CIN2/3 unknown → Local unknown                50.00
  **Regression rate**                             
   Regression state                               
    HPV → Well                                    
     20-24 yr                                     0.552
     25-29 yr                                     0.370
     ≥ 30 yr                                      0.103
    CIN1 →Well                                    
     20-34 yr                                     0.1449
     ≥ 35 yr                                      0.0738
    CIN1 → HPV                                    
     20-34 yr                                     0.0161
     ≥ 35 yr                                      0.0082
    CIN2/3 → Well                                 0.0345
    CIN2/3 → CIN1                                 0.0345
  **Cancerous state transition probability**      
   State                                          
    Local unknown → Regional unknown              14.8
    Regional unknown → Distant unknown            31.1

HPV, human papillomavirus; CIN, cervical intraepithelial neoplasia.

###### 

Cervical cancer screening program cost and utilities parameters

  Cost                                                                 Value
  -------------------------------------------------------------------- -----------
  **Screening cost^[a)](#tfn1-crt-2016-525){ref-type="table-fn"}^**    
   Primary screening costs (total=48,974)                              
    Pap smear test                                                     7,349
    Primary diagnosis                                                  15,159
    Consultation                                                       5,748
     Total                                                             28,256
    Transportation (one way)                                           6,247
     Total (×2)                                                        12,494
    Time                                                               7,954
    Postage of results                                                 270
   Secondary costs due to positive screening results (total=89,798)    
    Re-diagnosis                                                       11,395
    Specialty consultation                                             6,267
     Total                                                             17,662
    Mean^[b)](#tfn2-crt-2016-525){ref-type="table-fn"}^                32,057
    Time (×2)                                                          15,091
    Transportation                                                     6,247
     Total                                                             24,988
  **Treatment costs^[a)](#tfn1-crt-2016-525){ref-type="table-fn"}^**   
   Precancer treatment                                                 
    CIN1 treatment                                                     2,694,607
    CIN2/3 treatment                                                   5,184,292
   Cervical cancer treatment                                           
    Local                                                              4,585,303
    Regional                                                           4,907,512
    Distant                                                            7,860,224
   Cervical cancer follow up management at 1 yr                        
    Local                                                              1,642,859
    Regional                                                           1,641,271
    Distant                                                            1,650,366
   Cervical cancer follow up management at 2/3/4 yr                    
    Local                                                              871,275
    Regional                                                           870,433
    Distant                                                            875,257
  **Utility**                                                          
   State                                                               
    Well or well history                                               0.763
    CIN1                                                               0.714
    CIN2/3                                                             0.711
    Local                                                              0.496
    Regional                                                           0.477
    Distant                                                            0.366
   Sensitivity and specificity of Pap smear test                       
    CIN1 sensitivity                                                   0.77
    CIN2/3 sensitivity                                                 0.86
    Cancer sensitivity                                                 0.97
    Specificity                                                        0.58

CIN, cervical intraepithelial neoplasia.

All values are in Korean won (KRW),

Mean refers to the average colposcopy, biopsy, and human papillomavirus DNA test costs.

###### 

Costs, QALY, and ICER per capita of national cervical cancer screening program strategies

  Variable                                     Cost^[a)](#tfn3-crt-2016-525){ref-type="table-fn"}^   Incremental cost^[a)](#tfn3-crt-2016-525){ref-type="table-fn"}^   Effectiveness   Incremental effect   ICER
  -------------------------------------------- ----------------------------------------------------- ----------------------------------------------------------------- --------------- -------------------- ------------
  Current (baseline)                           25,661,227                                            \-                                                                44.5874         \-                   \-
  Strong recommendation to target regions      26,021,187                                            359,960                                                           44.6363         0.0489               7,361,145
  Regular universal screening recommendation   26,169,410                                            508,183                                                           44.6466         0.0592               8,584,172
  Strong universal screening recommendation    26,650,816                                            989,589                                                           44.6734         0.086                11,506,849

QALY, quality adjusted life years; ICER, incremental cost effectiveness ratio; CIN, cervical intraepithelial neoplasia.

Costs are in Korean won (KRW).

###### 

QALY and cost distribution per capita of regions

              Population   Current   Strong recommendation to target regions   Regular universal screening recommendation   Strong universal screening recommendation                                  
  ----------- ------------ --------- ----------------------------------------- -------------------------------------------- ------------------------------------------- -------- ------------ -------- ------------
  Daegu       49,866       44.520    2,220,040                                 44.520                                       2,220,040                                   44.615   2,224,782    44.638   2,225,944
  Gwangju     27,993       44.419    1,245,930                                 44.419                                       1,245,930                                   44.508   1,248,432    44.529   1,249,010
  Ulsan       21,256       44.234    942,145                                   44.234                                       942,145                                     44.316   943,885      44.336   944,326
  Incheon     54,618       44.599    2,440,842                                 44.599                                       2,440,842                                   44.681   2,445,313    44.702   2,446,485
  Seoul       208,613      45.185    9,445,269                                 45.185                                       9,445,269                                   45.268   9,462,577    45.289   9,466,967
  Daejeon     29,252       44.700    1,310,203                                 44.700                                       1,310,203                                   44.775   1,312,416    44.795   1,312,993
  Gyeonggi    228,556      44.838    10,268,755                                44.838                                       10,268,755                                  44.912   10,285,565   44.931   10,289,962
  Jeonnam     38,135       44.603    1,704,375                                 44.721                                       1,708,892                                   44.698   1,708,013    44.721   1,708,892
  Gyeongbuk   54,320       44.508    2,422,573                                 44.626                                       2,429,012                                   44.602   2,427,689    44.626   2,429,012
  Busan       72,917       45.137    3,297,875                                 45.253                                       3,306,372                                   45.230   3,304,684    45.253   3,306,372
  Jeju        11,047       45.025    498,412                                   45.144                                       499,733                                     45.121   499,471      45.144   499,733
  Jeonbuk     37,033       44.512    1,651,741                                 44.619                                       1,655,719                                   44.597   1,654,921    44.619   1,655,719
  Gyeongnam   39,194       44.475    2,875,704                                 44.58                                        2,882,520                                   44.559   2,881,162    44.580   2,882,520
  Chungnam    64,528       44.299    1,739,773                                 44.404                                       1,743,869                                   44.382   1,743,029    44.404   1,743,869
  Gangwon     30,380       44.524    1,355,388                                 44.627                                       1,358,524                                   44.605   1,357,863    44.627   1,358,524
  Chungbuk    30,371       44.619    1,357,881                                 44.720                                       1,360,954                                   44.699   1,360,309    44.720   1,360,954

Costs are in Korean won. QALY, quality adjusted life years.

[^1]: Tae-Hoon Lee and Woorim Kim contributed equally to this work.
